- Pulsenmore posted a net loss of USD 5 million, narrowing 50% from the prior year.
- Revenue climbed to USD 13 million, up 374% on a one-time USD 9.6 million contribution tied to a settlement with GE Precision Healthcare.
- Gross margin expanded to 84% from 37%.
- Operationally, Pulsenmore secured FDA clearance for remote-use prenatal ultrasound in the U.S. and received MDR CE certification in Europe for its Early-Screening pregnancy product.
- CEO Elazar Sonnenschein said focus in 2026 is accelerating commercial momentum, increasing utilization, and strengthening recurring revenue streams while maintaining disciplined investment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulsenmore Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603300829PR_NEWS_USPR_____LN22161) on March 30, 2026, and is solely responsible for the information contained therein.
Comments